HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Johannes Bonatti Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bonatti, J. Articles by Laufer, G. Search for Related Content PubMed PubMed Citation Articles by Bonatti, J. Articles by Laufer, G. Related Collections Cardiac - pharmacology Cardiac - other

Eur J Cardiothorac Surg 2002;21:981-986
© 2002 Elsevier Science NL

Acceptance of gene therapy by the heart surgery patient

Department of Cardiac Surgery and Institute of Medical Chemistry and Biochemistry, Innsbruck University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria

Received 15 November 2001; received in revised form 15 March 2002; accepted 15 March 2002.

* Corresponding author. Tel.: +43-512-504-3806; fax: +43-512-504-2528
e-mail: johannes.o.bonatti{at}uibk.ac.at

Objective: The aim of the present study was to evaluate the attitude of cardiac surgery patients towards gene therapeutic approaches to heart disease. Methods: One hundred and fifty patients having undergone coronary artery bypass grafting (n=97), valvular operations (n=40) or combined procedures (n=13) were personally interviewed prior to discharge using a self designed questionnaire. Results: Seventeen percent of the surveyed patients were unable to complete the interview because of total non-understanding of the topic. Of the remaining patients, 33% could basically define the term ‘gene’. After explanation of gene therapy principles 70% believed that gene therapy protocols had already been started clinically. Fifty-two percent would accept enrollment in a clinical trial (85% in cases of otherwise incurable disease). If clinical gene transfer would be carried out 73% of patients would accept adenovirus as a vector, 94 and 80%, respectively, would accept catheter-based intervention or surgery for performance of gene therapy. Fifty-four percent would agree to a prophylactic gene therapy protocol. Conclusions: We conclude that the general attitude of heart surgery patients regarding gene therapy is positive. A considerable number of patients are unable to understand the basic principles of gene therapy. These data can be useful for planning of clinical gene therapy trials and show potential difficulties in obtaining informed consent.

Key Words: Gene therapy • Cardiac surgery • Acceptance • Trials